Marshall Wace, LLP Ardelyx, Inc. Transaction History

Marshall Wace, LLP

$77.3 Billion
Q3 2024

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$6.05 - $9.74 $1.64 Million - $2.63 Million	270,466 New	270,466 $1.97 Million
Q1 2023 May 15, 2023	SELL	$2.68 - $4.79 $1.82 Million - $3.25 Million	-678,173 Reduced 91.22%	65,234 $312,000
Q4 2022 Feb 14, 2023	BUY	$1.22 - $2.85 $770,560 - $1.8 Million	631,607 Added 564.94%	743,407 $2.12 Million
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.44 $65,962 - $160,992	111,800 New	111,800 $132,000
Q2 2021 Aug 13, 2021	BUY	$6.55 - $8.98 $1.58 Million - $2.16 Million	240,628 Added 7.74%	3,348,363 $25.4 Million
Q1 2021 May 17, 2021	SELL	$6.1 - $7.69 $1.1 Million - $1.38 Million	-179,736 Reduced 5.47%	3,107,735 $20.6 Million
Q4 2020 Feb 16, 2021	BUY	$5.05 - $7.1 $14,271 - $20,064	2,826 Added 0.09%	3,287,471 $21.3 Million
Q3 2020 Nov 16, 2020	SELL	$5.25 - $7.08 $124,320 - $167,654	-23,680 Reduced 0.72%	3,284,645 $17.2 Million
Q2 2020 Aug 13, 2020	SELL	$5.37 - $8.11 $135,764 - $205,037	-25,282 Reduced 0.76%	3,308,325 $22.9 Million
Q1 2020 May 15, 2020	BUY	$4.35 - $8.79 $9.51 Million - $19.2 Million	2,186,199 Added 190.53%	3,333,607 $19 Million
Q4 2019 Feb 14, 2020	BUY	$4.23 - $8.29 $4.85 Million - $9.51 Million	1,147,408 New	1,147,408 $8.61 Million
Q4 2018 Feb 14, 2019	SELL	$1.66 - $4.16 $19,503 - $48,875	-11,749 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$3.75 - $4.65 $58,537 - $72,586	-15,610 Reduced 57.06%	11,749 $51,000
Q2 2018 Aug 14, 2018	BUY	$3.7 - $5.8 $57,757 - $90,538	15,610 Added 132.86%	27,359 $101,000
Q1 2018 May 15, 2018	BUY	$5.05 - $7.9 $59,332 - $92,817	11,749 New	11,749 $59,000

Others Institutions Holding ARDX

# of Institutions

219

Shares Held

141M

Call Options Held

1.08M

Put Options Held

View Full List

About ARDELYX, INC.

Ticker ARDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 154,636,000
Market Cap $815M
Description
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel synd...

More about ARDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Marshall Wace, LLP with notifications on news.

Account